# Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury.

> **NCT05711459** · NA · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 5405 (estimated)

## Conditions studied

- Drug-Induced Acute Liver Injury

## Interventions

- **DRUG:** Bicyclol tablets

## Key facts

- **NCT ID:** NCT05711459
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-01
- **Primary completion:** 2023-05-01
- **Final completion:** 2024-05-01
- **Target enrollment:** 5405 (ESTIMATED)
- **Last updated:** 2023-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05711459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05711459, "Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05711459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*